Peptide History
From Pituitary Extracts to Genetic Engineering: A Revolution in Medicine
The remarkable journey of Human Growth Hormone from its discovery in 1956 to becoming one of the most important therapeutic proteins in modern medicine.
Quick Facts
1956
Discovery
First isolated from human pituitary
191 amino acids
Structure
Single-chain polypeptide
1985
FDA Approval
First recombinant version approved
$5.2B+
Market Size
Annual global market value
The Visionaries
University of California, Berkeley
Biochemist & Endocrinologist
First to isolate and purify human growth hormone from pituitary glands in 1956, determining its amino acid sequence.
"The isolation of growth hormone opened a new chapter in our understanding of human development."
Genentech / UCSF
Geneticist & Entrepreneur
Co-founded Genentech and pioneered recombinant DNA technology that led to synthetic HGH production.
"Recombinant DNA technology gave us the power to produce human proteins safely and in unlimited quantities."
The Journey
The story of HGH begins in the laboratories of UC Berkeley, where Dr. Choh Hao Li spent years developing techniques to isolate hormones from human pituitary glands. The process was painstaking—it required thousands of cadaver pituitaries to produce enough hormone to treat a single child for one year. Despite the challenges, this work gave hope to children with growth hormone deficiency for the first time in history.
March 1985
Darkness Before Dawn
In 1985, the medical community faced a devastating crisis. Several patients who had received cadaver-derived HGH developed Creutzfeldt-Jakob disease (CJD), a fatal brain disorder. The FDA immediately halted distribution of pituitary-derived HGH. What seemed like a catastrophe became the catalyst for one of biotechnology's greatest achievements.
October 1985
Science Triumphs
Just months after the CJD crisis, Genentech received FDA approval for Protropin—the first recombinant human growth hormone. Using revolutionary DNA technology, scientists could now produce unlimited quantities of pure, safe HGH identical to the natural hormone. This marked the dawn of the biotechnology era and transformed HGH from a scarce resource into an accessible treatment.
Today, recombinant HGH treats numerous conditions beyond childhood growth deficiency, including adult GHD, Turner syndrome, chronic kidney disease, and HIV-related wasting. However, its powerful effects have also led to misuse in athletics and anti-aging, sparking ongoing debates about regulation, ethics, and the boundaries of medical enhancement.
Years of Progress
1956
First Isolation
Dr. Choh Hao Li successfully isolates human growth hormone from pituitary glands at UC Berkeley.
1958
First Clinical Use
HGH administered to growth-deficient children for the first time, showing remarkable results.
1971
Structure Revealed
Complete amino acid sequence of HGH determined, revealing its 191 amino acid structure.
1979
Recombinant Breakthrough
Genentech scientists successfully produce HGH using recombinant DNA technology.
1985
CJD Crisis
Discovery of CJD cases linked to cadaver-derived HGH leads to immediate FDA ban.
1985
FDA Approval
Genentech's Protropin becomes first recombinant HGH approved by FDA.
1987
Second Generation
Humatrope (Eli Lilly) approved—identical to natural 191-amino acid HGH.
1996
Adult Indication
FDA approves HGH for adult growth hormone deficiency.
2003
Idiopathic Short Stature
FDA expands approval to include children with idiopathic short stature.
2020s
Long-Acting Formulations
New weekly and monthly HGH formulations enter the market, improving patient compliance.
1956
First Isolation
Dr. Choh Hao Li successfully isolates human growth hormone from pituitary glands at UC Berkeley.
1958
First Clinical Use
HGH administered to growth-deficient children for the first time, showing remarkable results.
1971
Structure Revealed
Complete amino acid sequence of HGH determined, revealing its 191 amino acid structure.
1979
Recombinant Breakthrough
Genentech scientists successfully produce HGH using recombinant DNA technology.
1985
CJD Crisis
Discovery of CJD cases linked to cadaver-derived HGH leads to immediate FDA ban.
1985
FDA Approval
Genentech's Protropin becomes first recombinant HGH approved by FDA.
1987
Second Generation
Humatrope (Eli Lilly) approved—identical to natural 191-amino acid HGH.
1996
Adult Indication
FDA approves HGH for adult growth hormone deficiency.
2003
Idiopathic Short Stature
FDA expands approval to include children with idiopathic short stature.
2020s
Long-Acting Formulations
New weekly and monthly HGH formulations enter the market, improving patient compliance.
The Science
Imagine your body as a construction site where millions of tiny workers are constantly building and rebuilding. Growth hormone is the master foreman who coordinates all these workers.
191
Amino Acids
22,124 Da
Molecular Weight
20-30 min
Half-life
5.27
Isoelectric Point
Average growth rate in treated vs untreated children with GHD (cm/year)
Market value in billions USD over time
Your brain releases GHRH, signaling the pituitary gland to produce growth hormone.
The pituitary releases HGH into the bloodstream, where it travels throughout your body.
HGH triggers your liver to produce IGF-1, which together orchestrate growth and repair.
Global Impact
500,000+
Patients Treated Annually
Children and adults receiving HGH therapy worldwide
10+
FDA-Approved Indications
From growth deficiency to Turner syndrome and beyond
40+ Years
Of Safe Use
Recombinant HGH safety record since 1985
8-12 cm
Average Height Gain
Typical growth increase in deficient children over treatment
Diagnosed at Age 4
"I was the smallest kid in every class photo. At 4 years old, I was the size of a 2-year-old. Starting growth hormone therapy was like someone finally turned on the lights. I grew 6 inches that first year. Now I'm 28, 5'10", and I work as a pediatric nurse—helping kids like me."
Adult-Onset GHD
"After my pituitary surgery, I felt like I aged 20 years overnight. No energy, muscle weakness, depression. When my endocrinologist started me on growth hormone, it was gradual but profound. Six months later, I could play with my kids again. My husband said it was like getting his wife back."
Approved / In Development
Weekly and monthly HGH injections reducing treatment burden for patients.
Early Research
Research into oral HGH formulations that can survive digestive processes.
Preclinical
Potential for one-time treatments that restore natural HGH production.
Clinical Development
AI-driven algorithms to optimize individual HGH therapy protocols.
Be Inspired
Continue the legacy. The next breakthrough could be yours.